Pharmafile Logo
Pharmafocus logo
Advanced Search

breast cancer

Showing 15 posts of 177 posts found.

Novartis receives SMC approval for early breast cancer treatment

November 11, 2025
Research and Development Novartis, Scottish Medicines Consortium, breast cancer, nhs scotland

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval for use within NHS Scotland …

News

Micrima announces upcoming launch of new UK breast cancer assessment

October 3, 2025
Research and Development Micrima, breast cancer, oncology

Breast cancer remains one of the leading health threats to women over 35 in the UK Micrima, a healthcare technology …

News

Pierre Fabre partners with Know Your Lemons Foundation for breast cancer awareness

October 2, 2025
Medical Communications Education, Pierre Fabre, breast cancer

The campaign focuses on early detection and education Pierre Fabre Laboratories has announced a partnership with the Know Your Lemons …

News

Five Facts about Breast Cancer

October 2, 2025
Medical Communications Breast Cancer Awareness Month, Five Facts, Oncology, breast cancer

1 There are striking inequities in breast cancer burden regarding the Human Development Index (HDI), the United Nation’s measure of …

Feature
brain_scan_small

Duke Street Bio receives FDA fast track designation for brain metastases treatment

July 8, 2025
Medical Communications, Research and Development Duke Street Bio, Oncology, US Food and Drug Administration, brain metastases, breast cancer, fast track designation

Duke Street Bio, a biotech company based in London, UK, has announced that the US Food and Drug Administration (FDA) …

News

NICE recommendation for KORSERDU®▼ (elacestrant) marks ‘step-change’ in the treatment of ESR1-mutated metastatic breast cancer

December 19, 2024
ESR1, Menari Group, NICE, breast cancer, drug

Elacestrant is the first tailored treatment for certain people with oestrogen receptor (ER)-positive HER2-negative locally advanced and metastatic breast cancer …

News
Press release

Merck shares data from phase 3 trial of Keytruda for TNBC treatment

May 29, 2024
Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda

Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …

News

FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment

April 2, 2024
Research and Development AstraZeneca, Daiichi Sankyo, FDA, Oncology, bla, breast cancer

AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan (Dato-Dxd) has been accepted in …

News

Genentech shares positive results from phase 3 trial for breast cancer treatment

December 5, 2023
Research and Development Genentech, Oncology, breast cancer, oncology

Genentech, a member of the Roche Group, has announced positive results from the phase 3 INAVO120 study, which assessed the …

News

FDA approves AstraZeneca’s Truqap plus Faslodex for breast cancer treatment

November 17, 2023
Medical Communications AstraZeneca, FDA, Faslodex, Oncology, breast cancer

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with Faslodex (fullvestrant) …

News

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

September 22, 2023
Research and Development AstraZeneca, Daiichi Sankyo, Oncology, breast cancer, clinical trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, which showed datopotamab deruxtecan (Dato-DXd) …

News

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023
Medical Communications European Commission, Oncology, Orserdu, breast cancer

The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) has approved Orserdu (elacestrant) as …

News
cancer_cells_from_the_breast_cancer_now_tissue_bank_cell_programme

Merck shares data from phase 3 trial for breast cancer treatment

August 1, 2023
Research and Development MSD, Merck, Oncology, breast cancer, keytruda

Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 …

News
national-cancer-institute-kmvohcb-w5g-unsplash_1

FDA approves Pfizer’s HRR mCRPC drug

June 21, 2023
Medical Communications FDA, Oncology, Pfizer, breast cancer, oncology, prostate cancer

US-based pharmaceutical and biotechnology company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its homologous …

News
cancer_cells_from_the_breast_cancer_now_tissue_bank_cell_programme

AstraZeneca’s breast cancer drug given Priority Review by FDA

June 13, 2023
Business Services AstraZeneca, FDA, Oncology, breast cancer

UK-based pharmaceutical company AstraZeneca has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025